MCHM Macrochem (MM)

MacroChem CEO to Present at Bio 'Emerging Company Investor Forum' on October 15 in San Francisco LEXINGTON, Mass., Oct. 14 /PRNewswire-FirstCall/ -- MacroChem Corporation (NASDAQ:MCHM) has announced that Robert DeLuccia, its president and chief executive officer, will present on the Company's technologies, products and business strategies at the "BIO Emerging Company Investor Forum" in San Francisco on October 15. This forum is exclusively focused on the most promising public and late-stage private biotechnology and specialty pharmaceutical companies. The event has attracted over 200 companies that will present to many of the industry's prominent institutional and venture capital investors. In his presentation, Mr. DeLuccia will review the business strategy of MacroChem, a specialty pharmaceutical company developing innovative products by capitalizing on its proprietary transdermal drug delivery technology, SEPA(R). He will also discuss the status of the company's two SEPA-enhanced products in clinical development -- Opterone(R), a topical testosterone cream for treating male hypogonadism, and EcoNail(TM), an econazole nail lacquer for treating onychomycosis (fungal nail infections). This call is being webcast by CCBN and can be accessed at MacroChem's web site at http://www.macrochem.com/ . The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at http://www.fulldisclosure.com/ or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (http://www.streetevents.com/). The web address of MacroChem's presentation is http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=MCHM&item_id=949877 About MacroChem MacroChem is a specialty pharmaceutical company that innovates, develops and commercializes pharmaceuticals administered in novel ways, to treat important medical conditions. MacroChem is developing two products containing its patented enhancer, SEPA: Opterone(TM), a SEPA-enhanced topical treatment for men with testosterone deficiency; and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis. With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. DATASOURCE: MacroChem CONTACT: Investors, Bernard Patriacca, VP/CFO of MacroChem, +1-781-862-4003, Media, Donna LaVoie of LaVoie Group, +1-781-596-0200, ext. 103 Web site: http://www.macrochem.com/ http://www.fulldisclosure.com/ http://www.streetevents.com/ http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=MCHM&item_id=949877

Copyright